drugset / Trial / NCT00317798
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Biological therapies, such as antithymocyte globulin may stimulate the immune system in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also prevent or reduce the side effects of antithymocyte globulin. Giving antithymocyte globulin together with sirolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of antithymocyte globulin when given together with sirolimus in treating patients with relapsed multiple myeloma.
Timeline
- Start
- 2006-04
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymoglobulin | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | Thymoglobulin | Protein / enzyme biologic | 14.5 mg/kg | Intravenous |
| Background | Sirolimus | Small molecule | 1 mg | Oral |